- Home
- Healthcare professionals
- ACE Technology Guidances
- Drug Guidance
- Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
Botulinum toxin A for the management of focal spasticity of the lower limbs associated with stroke in adults
Musculoskeletal
1 June 2023
Published on 01 Jun 2023
Last Updated on 01 Jun 2023
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for the management of focal spasticity of the lower limbs associated with stroke in adults who:
have a score of 3 or more on the Modified Ashworth Scale at the target muscle intended for botulinum toxin A treatment;
do not have the affected joint permanently fixed in position due to fibrotic shortening of the target muscle; and
are concurrently receiving physiotherapy.
Funding status
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.
Botulinum toxin A must be administered by either a neurologist trained in movement disorder or a rehabilitation physician who has undergone training to administer botulinum toxin A.
MAF assistance does not apply to Botox 200 U injection vial or other brands of botulinum toxin A.